Graft

(redirected from Graft rejection)
Also found in: Dictionary, Thesaurus, Medical, Legal, Encyclopedia.
Related to Graft rejection: Graft versus host disease

Graft

An informal term for bribery.
References in periodicals archive ?
Basically, graft rejection is prevented by the anti-inflammatory properties of the amniotic membrane.
It also reviews key players involved in the therapeutic development for Corneal Graft Rejection and special features on late-stage and discontinued projects.
UKPRwire, Tue May 27 2014] Corneal Graft Rejection - Pipeline Review, H1 2014
The adhering cells have low immunogenicity which minimizes the risk of immune reaction and graft rejection and also eliminates the need for immunosuppressive drugs.
The hope is that skin or other cells from individuals with MS could one day be used as a source for reparative stem cells, which could then be transplanted back into the patient without the complications of graft rejection.
1 When vessels are present on the cornea then chances of graft rejection are very high, and it is considered as a high risk corneal graft surgery.
Mr Musa said he was now hoping the surgery would become more popular as it offered quicker healing time, better quality vision and reduced the risk of graft rejection, which is present in any transplant, to less than 1%.
They include patients in need of rapid engraftment, such as those with life-threatening infections, or patients at high risk for graft rejection, such as those who receive reduced-intensity conditioning that does not include intensive chemotherapy.
Patients who have donor-specific anti-HLA antibodies before transplantation have poor graft outcomes, with the vast majority of cases of antibody-mediated renal graft rejection attributed to anti-HLA antibodies.
PHILADELPHIA - Women who become pregnant after receiving a transplanted liver face an elevated risk of graft rejection, especially during or immediately following the pregnancy, based on a review of 161 U.
Bristol-Myers Squibb Company (NYSE:BMY) reported on Wednesday the receipt of approval from the US Food & Drug Administration (FDA) for NULOJIX (belatacept) for the prevention of graft rejection after kidney transplants.